Ghrelin and Obestatin in CKD Children
Anahtar kelimeler
Öz
Açıklama
This is a cross-sectional case-control study. Between January 2013 and June 2015 children and adolescents aged 5-20 years, referred to the Pediatric Nephrology, Dialysis and Transplant Unit of Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico - Milan, Italy were enrolled. Subjects with CKD stages II-V under conservative treatment (CKD-CT), or undergoing hemodialysis treatment (CKD-HD), or being renal transplant recipients (RTx) were included in the study. Data about age, primary renal disease and concomitant medications were collected for each subject.
CKD stages were defined using the K/DOQI criteria of the US National Kidney Foundation.
Control subjects were outpatients of the Pediatric Surgery Unit of the Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico - Milan, Italy, aged 1-20 years, who underwent a blood sample collection before a surgical intervention for the treatment of minor diseases that did not impair renal or endocrine function (i.e. phimosis, hydrocele, inguinal hernia).
Biochemical and hormonal parameters Blood samples were collected between 7:00 and 8:00 a.m. after an overnight fast, and before dialysis in CKD-HD patients. Routine biochemical parameters [creatinine, urea] were measured in all subjects. Glomerular filtration rate was estimated (eGFR) by the Schwartz formula, with k = 0.413, as appropriate for standardized creatinine.
In all subjects, plasma AG and UAG concentrations were measured by the Human Acylated / Unacylated Ghrelin ELISA kit (BioVendor, Laboratorni Medicina a.s., Brno, Czech Republic) according to manufacture procedures, and AG/UAG ratio was calculated. Serum obestatin concentrations were determined using the Human Obestatin ELISA kit (BioVendor, Laboratorni Medicina a.s., Brno, Czech Republic).
Tarih
| Son Doğrulandı: | 04/30/2017 |
| İlk Gönderilen: | 05/24/2017 |
| Tahmini Kayıt Gönderildi: | 05/27/2017 |
| İlk Gönderilen: | 05/30/2017 |
| Son Güncelleme Gönderildi: | 05/27/2017 |
| Son Güncelleme Gönderildi: | 05/30/2017 |
| Fiili Çalışma Başlangıç Tarihi: | 12/31/2012 |
| Tahmini Birincil Tamamlanma Tarihi: | 06/29/2015 |
| Tahmini Çalışma Tamamlanma Tarihi: | 06/29/2015 |
Durum veya hastalık
Müdahale / tedavi
Other: none intervention
Evre
Kol Grupları
| Kol | Müdahale / tedavi |
|---|---|
| CKD-CT subjects with CKD stages II-V under conservative treatment | |
| CKD-HD subjects with CKD stage V on hemodialysis | |
| RTx renal transplant renal transplant recipients | |
| Controls control subjects |
Uygunluk kriterleri
| Çalışmaya Uygun Yaşlar | 5 Years İçin 5 Years |
| Çalışmaya Uygun Cinsiyetler | All |
| Örnekleme yöntemi | Probability Sample |
| Sağlıklı Gönüllüleri Kabul Ediyor | Evet |
| Kriterler | Inclusion Criteria: - the CKD-HD patients should have been on hemodialysis treatment for at least 3 months - the RTx patients should have received renal transplantation at least 6 months before Exclusion Criteria: - treatment with growth hormone - the presence of neurologic disability or syndromic diseases affecting per se food intake - for controls: they should have no history of chronic diseases and should not receive any medication. They should be on unrestricted diet. |
Sonuç
Birincil Sonuç Ölçütleri
1. AG concentrations by ELISA kit on plasma samples [January 2013-June 2015]
2. UAG concentrations by ELISA kit on plasma samples [January 2013-June 2015]
3. Obestatin concentrations by ELISA kit on serum samples [January 2013-June 2015]
